Nuvectis Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 13
- Market Cap
- $130M
- Website
- http://nuvectis.com
- Introduction
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Nuvectis Pharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05873686
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
- Conditions
- Advanced Solid TumorARID1A Gene MutationOvarian Clear Cell TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian CancerOvarian Clear Cell CarcinomaOvarian Endometrioid Tumor
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Nuvectis Pharma, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05226507
- Locations
- 🇺🇸
Honor Health, Phoenix, Arizona, United States
🇺🇸UC San Diego Health - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
News
Nuvectis Pharma to Present Promising NXP900 Data at 2025 AACR Meeting
Nuvectis Pharma will showcase five presentations on their novel SRC/YES1 inhibitor NXP900 at the 2025 AACR Meeting in Chicago from April 25-30, highlighting its potential in multiple cancer types.
Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial
Nuvectis Pharma's NXP800 demonstrates antitumor activity in a Phase 1b study for ARID1a-mutated ovarian cancer resistant to platinum-based chemotherapy.
Nuvectis Pharma Reports Financial Results and Highlights Clinical Progress of NXP800 and NXP900
Nuvectis Pharma reported a net loss of $4.2 million for the quarter ended September 30, 2024, a decrease of $1.7 million compared to the same period in 2023.